GlassScriptPhysician profile
Stacy Ann Paggi
NPI 1669502993
$5,608.56
in general payments reported to CMS, 2019-2025
28 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 88% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $230 · 2021: $366 · 2022: $428 · 2023: $1,066 · 2024: $1,326 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,654 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,654.32 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $600.30 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $490.34 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $468.45 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $457.63 | 2019-2024 | Jornay Pm |
| Lundbeck LLC | $390.11 | 2019-2025 | Rexulti, Brintellix |
| Sunovion Pharmaceuticals INC. | $353.76 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $333.45 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $323.86 | 2023-2025 | Caplyta |
| Corium, LLC | $234.64 | 2023-2025 | Azstarys, Azstarys |
| Shire North American Group INC | $228.37 | 2019 | |
| Tris Pharma INC | $225.15 | 2019-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $188.47 | 2023-2025 | Aplenzin |
| Alkermes, INC. | $171.28 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $170.06 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $166.73 | 2024-2025 | Fanapt, Hetlioz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $145.37 | 2019-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $145.36 | 2023-2025 | |
| Allergan, INC. | $121.87 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $81.85 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $78.18 | 2019-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $67.99 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $62.06 | 2019-2024 | Ingrezza |
| Noven Pharmaceuticals, INC. | $19.72 | 2024 | Xelstrym |
| Almatica Pharma LLC | $19.46 | 2023 | Loreev Xr |
| Tms Neurohealth Centers INC. | $19.26 | 2025 | Tms Neurohealth Centers INC. |
| Vertical Pharmaceuticals, LLC | $17.54 | 2024 | Relexxii |
| Idorsia Pharmaceuticals US INC | $16.01 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Paggi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.